Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Day One Biopharmaceuticals (DAWN) EBITDA Margin: 2024-2025

Historic EBITDA Margin for Day One Biopharmaceuticals (DAWN) over the last 2 years, with Sep 2025 value amounting to -60.94%.

  • Day One Biopharmaceuticals' EBITDA Margin fell 9255.00% to -60.94% in Q3 2025 from the same period last year, while for Sep 2025 it was -123.90%, marking a year-over-year change of. This contributed to the annual value of -165.65% for FY2024, which is N/A change from last year.
  • Per Day One Biopharmaceuticals' latest filing, its EBITDA Margin stood at -60.94% for Q3 2025, which was up 40.92% from -103.14% recorded in Q2 2025.
  • Day One Biopharmaceuticals' 5-year EBITDA Margin high stood at 31.61% for Q3 2024, and its period low was -1,401.45% during Q2 2024.
  • Its 2-year average for EBITDA Margin is -315.19%, with a median of -118.32% in 2025.
  • The largest annual percentage gain for Day One Biopharmaceuticals' EBITDA Margin in the last 5 years was 129,831bps (2025), contrasted with its biggest fall of 9,255bps (2025).
  • Over the past 2 years, Day One Biopharmaceuticals' EBITDA Margin (Quarterly) stood at -223.68% in 2024, then crashed by 9,255bps to -60.94% in 2025.
  • Its EBITDA Margin stands at -60.94% for Q3 2025, versus -103.14% for Q2 2025 and -133.50% for Q1 2025.